


## Amendments to the claims

1. (currently amended) A compound of Formula (I):



or a stereoisomer, or pharmaceutically acceptable salt form or prodrug thereof, wherein:

$A^1$  is  $C_1-C_3$  alkylene substituted by 0-2  $C_1-C_4$  alkyl;

$A^2$  is  $-C(=O)R^{9b}$ ,  $-S(=O)R^{9b}$ ,  $-S(=O)_2R^{9b}$ ,  $-CONHR^{9b}$ ,

$-S(=O)_2NHR^{9b}$ ,  $-C(=O)OR^{9b}$ ,

$-A^3-R^{9a}$ ;

$-A^3-A^4-R^{9a}$ ,

$-A^3-A^4-A^5-R^{9a}$ , or

$-A^3-A^4-A^5-A^6-R^{9a}$ ,

$W$  is selected from the group:

$-B(OR^{26})(OR^{27})$ ,

$-C(=O)C(=O)Q$ ,

$-C(=O)C(=O)NHQ$ ,

$-C(=O)C(=O)OQ$ ,

$-C(=O)CF_2C(=O)NHQ$ ,

$-C(=O)CF_3$ ,

$-C(=O)CF_2CF_3$ ,

$-C(=O)H$ , and

$-C(=O)W^1$ ;

$W^1$  is  $OR^8$  or  $NR^{11}R^{11a}$ ,

$Q$  is selected from the group:

$-(CR^{10}R^{10e})_m Q^1,$

$-(CR^{10}R^{10e})_m Q^2,$

$C_1-C_4$  alkyl substituted with  $Q^1,$

$C_2-C_4$  alkenyl substituted with  $Q^1,$

$C_2-C_4$  alkynyl substituted with  $Q^1,$

an amino acid residue,

$-A^7-A^8,$  and

$-A^7-A^8-A^9,$

$m$  is 1, 2, 3, or 4;

$Q^1$  is selected from the group:

$-CO_2R^{11}, -SO_2R^{11}, -SO_3R^{11}, -P(O)_2R^{11}, -P(O)_3R^{11},$

aryl substituted with 0-4  $Q^{1a};$  and

5-6 membered heterocyclic group consisting of carbon atoms and

1-4 heteroatoms selected from the group: O, S, and N;

optionally saturated, partially unsaturated or unsaturated;

and said 5-6 membered heterocyclic group is substituted

with 0-4  $Q^{1a},$

$Q^{1a}$  is H, F, Cl, Br, I,  $NO_2$ ,  $CN$ ,  $NCS$ ,  $CF_3$ ,  $OCF_3,$

$-CO_2R^{19}, -C(=O)NR^{19}R^{19a}, -NHC(=O)R^{19}, -SO_2R^{19},$

$-SO_2NR^{19}R^{19a}, -NR^{19}R^{19a}, -OR^{19}, -SR^{19}, C_1-C_4$  alkyl,

$C_1-C_4$  alkoxy,  $C_1-C_4$  haloalkyl, or  $C_1-C_4$  haloalkoxy,

$Q^2$  is  $X-NR^{12}-Z$ ,  $NR^{12}-Y-Z$ , or  $X-NR^{12}-Y-Z$ ,

$X$  is  $C(=O)$ ,  $S$ ,  $S(=O)$ ,  $S(=O)_2$ ,  $P(O)$ ,  $P(O)_2$ , or  
 $-P(O)_3$ ;

$Y$  is  $C(=O)$ ,  $S$ ,  $S(=O)$ ,  $S(=O)_2$ ,  $P(O)$ ,  $P(O)_2$ , or  
 $-P(O)_3$ ;

$Z$  is selected from the group:

$C_1-C_4$  haloalkyl,

$C_1-C_4$  alkyl substituted with  $0-3 Z^a$ ,

$C_2-C_4$  alkenyl substituted with  $0-3 Z^a$ ,

$C_2-C_4$  alkynyl substituted with  $0-3 Z^a$ ,

$C_3-C_{10}$  cycloalkyl substituted with  $0-5 Z^b$ ,

aryl substituted with  $0-5 Z^b$ ,

$5-10$  membered heterocyclic group consisting of carbon atoms and  $1-4$  heteroatoms selected from the group:  $O$ ,  $S$ , and  $N$ , optionally saturated, partially unsaturated or unsaturated, and said  $5-10$  membered heterocyclic group is substituted with  $0-4 Z^b$ ,

an amino acid residue,

$-A^7-A^8$ , and

$-A^7-A^8-A^9$ ,

$Z^a$  is selected from the group:

$H$ ,  $F$ ,  $Cl$ ,  $Br$ ,  $I$ ,  $NO_2$ ,  $CN$ ,  $NCS$ ,  $CF_3$ ,  $OCF_3$ ,

$-CO_2R^{20}$ ,  $C(=O)NR^{20}R^{20a}$ ,  $NHC(=O)R^{20}$ ,  $NR^{20}R^{20a}$ ,

$\text{-OR}^{20}$ ,  $\text{SR}^{20}$ ,  $\text{S}(\text{=O})\text{R}^{20}$ ,  $\text{SO}_2\text{R}^{20}$ ,  $\text{SO}_2\text{NR}^{20}\text{R}^{20a}$ ,  $\text{C}_1\text{-C}_4\text{-alkyl}$ ,  
 $\text{C}_1\text{-C}_4\text{-haloalkyl}$ ,  $\text{C}_1\text{-C}_4\text{-haloalkoxy}$ ,  
 $\text{C}_3\text{-C}_{10}\text{-cycloalkyl substituted with 0-5 Z}^b$ ,  
 $\text{C}_3\text{-C}_{10}\text{-carboycile substituted with 0-5 Z}^b$ ,  
 $\text{aryl substituted with 0-5 Z}^b$ , and  
 $\text{5-10 membered heterocyclic group consisting of carbon atoms}$   
 $\text{and 1-4 heteroatoms selected from the group: O, S, and N;}$   
 $\text{optionally saturated, partially unsaturated or unsaturated,}$   
 $\text{and said 5-10 membered heterocyclic group is substituted}$   
 $\text{with 0-4 Z}^b$ ;

$\text{Z}^b$  is selected from the group:

$\text{H, F, Cl, Br, I, NO}_2$ ,  $\text{CN, NCS, CF}_3$ ,  $\text{OCF}_3$ ,  
 $\text{-CO}_2\text{R}^{20}$ ,  $\text{C}(\text{=O})\text{NR}^{20}\text{R}^{20a}$ ,  $\text{NHC}(\text{=O})\text{R}^{20}$ ,  $\text{NR}^{20}\text{R}^{20a}$ ,  
 $\text{-OR}^{20}$ ,  $\text{SR}^{20}$ ,  $\text{S}(\text{=O})\text{R}^{20}$ ,  $\text{SO}_2\text{R}^{20}$ ,  $\text{SO}_2\text{NR}^{20}\text{R}^{20a}$ ,  $\text{C}_1\text{-C}_4\text{-alkyl}$ ,  
 $\text{C}_1\text{-C}_4\text{-haloalkyl}$ ,  $\text{C}_1\text{-C}_4\text{-haloalkoxy}$ ,  
 $\text{C}_3\text{-C}_{10}\text{-cycloalkyl substituted with 0-5 Z}^e$ ,  
 $\text{C}_3\text{-C}_{10}\text{-carboycile substituted with 0-5 Z}^e$ ,  
 $\text{aryl substituted with 0-5 Z}^e$ , and  
 $\text{5-10 membered heterocyclic group consisting of carbon atoms}$   
 $\text{and 1-4 heteroatoms selected from the group: O, S, and N;}$   
 $\text{optionally saturated, partially unsaturated or unsaturated,}$   
 $\text{and said 5-10 membered heterocyclic group is substituted}$   
 $\text{with 0-4 Z}^e$ ;

$\text{Z}^e$  is  $\text{H, F, Cl, Br, I, NO}_2$ ,  $\text{CN, NCS, CF}_3$ ,  $\text{OCF}_3$ ,  
 $\text{-CO}_2\text{R}^{20}$ ,  $\text{C}(\text{=O})\text{NR}^{20}\text{R}^{20a}$ ,  $\text{NHC}(\text{=O})\text{R}^{20}$ ,  $\text{NR}^{20}\text{R}^{20a}$ ,

$\text{--OR}^{20}$ ,  $\text{--SR}^{20}$ ,  $\text{--S(=O)R}^{20}$ ,  $\text{--SO}_2\text{R}^{20}$ ,  $\text{--SO}_2\text{NR}^{20}\text{R}^{20a}$ ,  $\text{C}_1\text{--C}_4\text{--alkyl}$ ,  
 $\text{C}_1\text{--C}_4\text{--haloalkyl}$ , or  $\text{C}_1\text{--C}_4\text{--haloalkoxy}$ ;

$\text{R}^1$  is selected from the group: H, F;

$\text{C}_1\text{--C}_6$  alkyl substituted with 0-3  $\text{R}^{1a}$ ;

$\text{C}_2\text{--C}_6$  alkenyl substituted with 0-3  $\text{R}^{1a}$ ;

$\text{C}_2\text{--C}_6$  alkynyl substituted with 0-3  $\text{R}^{1a}$ ; and

$\text{C}_3\text{--C}_6$  cycloalkyl substituted with 0-3  $\text{R}^{1a}$ ;

$\text{R}^{1a}$  is selected at each occurrence from the group:

Cl, F, Br, I,  $\text{CF}_3$ ,  $\text{CHF}_2$ , OH, =O, SH,  $\text{CO}_2\text{R}^{1b}$ ,  $\text{SO}_2\text{R}^{1b}$ ,

$\text{SO}_3\text{R}^{1b}$ ,  $\text{P(O)}_2\text{R}^{1b}$ ,  $\text{P(O)}_3\text{R}^{1b}$ ,  $\text{C(=O)NHR}^{1b}$ ,

$\text{--NHC(=O)R}^{1b}$ ,  $\text{SO}_2\text{NHR}^{1b}$ ,  $\text{--OR}^{1b}$ ,  $\text{--SR}^{1b}$ ,  $\text{C}_3\text{--C}_6$  cycloalkyl,  $\text{C}_1\text{--C}_6$

alkoxy,  $\text{S(C}_1\text{--C}_6\text{--alkyl)}$ ;

$\text{C}_1\text{--C}_4$  alkyl substituted with 0-3  $\text{R}^{1e}$ ;

aryl substituted with 0-5  $\text{R}^{1e}$ ;

$\text{--O(CH}_2\text{)}_n\text{--aryl}$  substituted with 0-5  $\text{R}^{1e}$ ;

$\text{--S(CH}_2\text{)}_n\text{--aryl}$  substituted with 0-5  $\text{R}^{1e}$ ; and

5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N; optionally saturated, partially unsaturated or unsaturated, and said 5-10 membered heterocyclic group is substituted with 0-3  $\text{R}^{1e}$ ;

$n$  is 0, 1 or 2;

$\text{R}^{1b}$  is H;

$\text{C}_1\text{-C}_4$  alkyl substituted with 0-3  $\text{R}^{1e}$ ;

$\text{C}_2\text{-C}_4$  alkenyl substituted with 0-3  $\text{R}^{1e}$ ;

$\text{C}_2\text{-C}_4$  alkynyl substituted with 0-3  $\text{R}^{1e}$ ;

$\text{C}_3\text{-C}_6$  cycloalkyl substituted with 0-5  $\text{R}^{1e}$ ;

aryl substituted with 0-5  $\text{R}^{1e}$ ;

aryl  $\text{C}_1\text{-C}_4$  alkyl substituted with 0-4  $\text{R}^{1e}$ ; or

5-6 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N; optionally saturated, partially unsaturated or unsaturated, and said 5-10 membered heterocyclic group is substituted with 0-4  $\text{R}^{1e}$ ;

$\text{R}^{1e}$  is selected at each occurrence from the group:

$\text{C}_1\text{-C}_4$  alkyl, Cl, F, Br, I, OH, SH, CN,  $\text{NO}_2$ ,  $\text{OR}^{1d}$ ,  $-\text{C}(=\text{O})\text{OR}^{1d}$ ,  $\text{NR}^{1d}\text{R}^{1d}$ ,  $\text{SO}_2\text{R}^{1d}$ ,  $\text{SO}_3\text{R}^{1d}$ ,  $\text{C}(=\text{O})\text{NHR}^{1d}$ ,  $-\text{NHC}(=\text{O})\text{R}^{1d}$ ,  $\text{SO}_2\text{NHR}^{1d}$ ,  $\text{CF}_3$ ,  $\text{OCF}_3$ ,  $\text{C}_3\text{-C}_6$  cycloalkyl, phenyl, and benzyl;

$\text{R}^{1d}$  is selected at each occurrence from the group: H,  $\text{C}_1\text{-C}_4$  alkyl, phenyl and benzyl;

$\text{R}^2$  is selected from the group: H,  $\text{C}_1\text{-C}_4$  alkyl,  $\text{C}_2\text{-C}_4$  alkenyl,  $\text{C}_2\text{-C}_4$  alkynyl,  $\text{C}_3\text{-C}_4$  cycloalkyl, and  $\text{C}_3\text{-C}_4$  cycloalkyl( $\text{C}_1\text{-C}_4$  alkyl)-;

alternatively,  $\text{R}^1$  and  $\text{R}^2$  can be combined to form a 4-7 membered cyclic group consisting of carbon atoms, substituted with 0-2  $\text{R}^{14}$ ;

$R^3$  is selected from the group:  $R^4$ ,

-(CH<sub>2</sub>)<sub>p</sub>-NH- $R^4$ ,  
-(CH<sub>2</sub>)<sub>p</sub>-NHC(=O)- $R^4$ ,  
-(CH<sub>2</sub>)<sub>p</sub>-C(=O)NH- $R^4$ ,  
-(CH<sub>2</sub>)<sub>p</sub>-C(=O)O- $R^4$ ,  
-(CH<sub>2</sub>)<sub>p</sub>-C(=O)C(=O)- $R^4$ ,  
-(CH<sub>2</sub>)<sub>p</sub>-C(=O)C(=O)NH- $R^4$ ,  
-(CH<sub>2</sub>)<sub>p</sub>-NHC(=O)NH- $R^4$ ,  
-(CH<sub>2</sub>)<sub>p</sub>-NHC(=O)NHC(=O)- $R^4$ ,  
-(CH<sub>2</sub>)<sub>p</sub>-NHS(=O)<sub>2</sub>- $R^4$ ,  
-(CH<sub>2</sub>)<sub>p</sub>-S(=O)<sub>2</sub>NH- $R^4$ ,  
-(CH<sub>2</sub>)<sub>p</sub>-C(=O)- $R^4$ ,  
-(CH<sub>2</sub>)<sub>p</sub>-O- $R^4$ , and  
-(CH<sub>2</sub>)<sub>p</sub>-S- $R^4$ ;

$p$  is 0, 1, or 2;

$R^4$  is selected from the group:

C<sub>1</sub>-C<sub>6</sub> alkyl substituted with 0-3  $R^{4a}$ ;  
C<sub>2</sub>-C<sub>6</sub> alkenyl substituted with 0-3  $R^{4a}$ ;  
C<sub>2</sub>-C<sub>6</sub> alkynyl substituted with 0-3  $R^{4a}$ ;  
C<sub>3</sub>-C<sub>10</sub> cycloalkyl substituted with 0-4  $R^{4b}$ ;  
C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-4  $R^{4b}$ ;  
aryl substituted with 0-5  $R^{4b}$ ; and  
aryl-C<sub>1</sub>-C<sub>4</sub> alkyl substituted with 0-5  $R^{4b}$ ; and

~~5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N; optionally saturated, partially unsaturated or unsaturated; and said 5-10 membered heterocyclic group is substituted with 0-4 R<sup>4b</sup>;~~

R<sup>4a</sup> is, at each occurrence, independently selected from:

~~H, F, Cl, Br, I, NO<sub>2</sub>, CN, NCS, CF<sub>3</sub>, OCF<sub>3</sub>,~~  
~~=O, OH, CO<sub>2</sub>H, C(=NH)NH<sub>2</sub>, CO<sub>2</sub>R<sup>11</sup>, C(=O)NR<sup>11</sup>R<sup>11a</sup>,~~  
~~NHC(=O)R<sup>11</sup>, NR<sup>11</sup>R<sup>11a</sup>, OR<sup>11a</sup>, SR<sup>11a</sup>, C(=O)R<sup>11a</sup>,~~  
~~S(=O)R<sup>11a</sup>, SO<sub>2</sub>R<sup>11</sup>, SO<sub>2</sub>NR<sup>11</sup>R<sup>11a</sup>, NHC(=NH)NHR<sup>11</sup>,~~  
~~C(=NH)NHR<sup>11</sup>, =NOR<sup>11</sup>, NR<sup>11</sup>C(=O)OR<sup>11a</sup>,~~  
~~NR<sup>11</sup>C(=O)NR<sup>11</sup>R<sup>11a</sup>, NR<sup>11</sup>SO<sub>2</sub>NR<sup>11</sup>R<sup>11a</sup>, NR<sup>11</sup>SO<sub>2</sub>R<sup>11a</sup>,~~  
~~OP(O)(OR<sup>11</sup>)<sub>2</sub>~~

C<sub>1</sub>-C<sub>4</sub> alkyl substituted with 0-3 R<sup>4b</sup>;

C<sub>2</sub>-C<sub>4</sub> alkenyl substituted with 0-3 R<sup>4b</sup>;

C<sub>2</sub>-C<sub>4</sub> alkynyl substituted with 0-3 R<sup>4b</sup>;

C<sub>3</sub>-C<sub>7</sub> cycloalkyl substituted with 0-4 R<sup>4c</sup>;

C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-4 R<sup>4c</sup>; and

aryl substituted with 0-5 R<sup>4c</sup>; and

~~5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N; optionally saturated, partially unsaturated or unsaturated; and said 5-10 membered heterocyclic group is substituted with 0-3 R<sup>4e</sup>;~~

R<sup>4b</sup> is, at each occurrence, independently selected from:

~~H, F, Cl, Br, I, NO<sub>2</sub>, CN, NCS, CF<sub>3</sub>, OCF<sub>3</sub>, =O, OH, CO<sub>2</sub>H,~~  
~~-C(=NH)NH<sub>2</sub>, CO<sub>2</sub>R<sup>11</sup>, C(=O)NR<sup>11</sup>R<sup>11a</sup>,~~  
~~-NHC(=O)R<sup>11</sup>, NR<sup>11</sup>R<sup>11a</sup>, OR<sup>11a</sup>, SR<sup>11a</sup>, C(=O)R<sup>11a</sup>,~~  
~~-S(=O)R<sup>11a</sup>, SO<sub>2</sub>R<sup>11</sup>, SO<sub>2</sub>NR<sup>11</sup>R<sup>11a</sup>, NHC(=NH)NHR<sup>11</sup>,~~  
~~-C(=NH)NHR<sup>11</sup>, =NOR<sup>11</sup>, NR<sup>11</sup>C(=O)OR<sup>11a</sup>,~~  
~~-OC(=O)NR<sup>11</sup>R<sup>11a</sup>, NR<sup>11</sup>C(=O)NR<sup>11</sup>R<sup>11a</sup>, NR<sup>11</sup>SO<sub>2</sub>NR<sup>11</sup>R<sup>11a</sup>,~~  
~~NR<sup>11</sup>SO<sub>2</sub>R<sup>11a</sup>, OP(O)(OR<sup>11</sup>)<sub>2</sub>,~~

C<sub>1</sub>-C<sub>4</sub> alkyl substituted with 0-3 R<sup>4c</sup>;

C<sub>2</sub>-C<sub>4</sub> alkenyl substituted with 0-3 R<sup>4c</sup>;

C<sub>2</sub>-C<sub>4</sub> alkynyl substituted with 0-3 R<sup>4c</sup>;

C<sub>3</sub>-C<sub>6</sub> cycloalkyl substituted with 0-4 R<sup>4d</sup>; and

aryl substituted with 0-5 R<sup>4d</sup>; and

~~5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, optionally saturated or unsaturated; and said 5-10 membered heterocyclic group is substituted with 0-3 R<sup>4d</sup>,~~

R<sup>4c</sup> is, at each occurrence, independently selected from:

~~H, F, Cl, Br, I, NO<sub>2</sub>, CN, NCS, CF<sub>3</sub>, OCF<sub>3</sub>, =O, OH, CO<sub>2</sub>H,~~  
~~-C(=NH)NH<sub>2</sub>, CO<sub>2</sub>R<sup>11</sup>, C(=O)NR<sup>11</sup>R<sup>11a</sup>,~~  
~~-NHC(=O)R<sup>11</sup>, NR<sup>11</sup>R<sup>11a</sup>, OR<sup>11a</sup>, SR<sup>11a</sup>, C(=O)R<sup>11a</sup>,~~  
~~-S(=O)R<sup>11a</sup>, SO<sub>2</sub>R<sup>11</sup>, SO<sub>2</sub>NR<sup>11</sup>R<sup>11a</sup>,~~  
~~C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> haloalkoxy,~~

C<sub>1</sub>-C<sub>4</sub> alkyl substituted with 0-3 R<sup>4d</sup>;

C<sub>2</sub>-C<sub>4</sub> alkenyl substituted with 0-3 R<sup>4d</sup>;

C<sub>2</sub>-C<sub>4</sub> alkynyl substituted with 0-3 R<sup>4d</sup>;

C<sub>3</sub>-C<sub>6</sub> cycloalkyl substituted with 0-4 R<sup>4d</sup>; and

aryl substituted with 0-5  $R^{4d}$ ; and  
~~5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, optionally saturated or unsaturated; and said 5-10 membered heterocyclic group is substituted with 0-3  $R^{4d}$ ,~~

$R^{4d}$  is, at each occurrence, independently selected from:

$H$ ,  $F$ ,  $Cl$ ,  $Br$ ,  $I$ ,  $-NO_2$ ,  $-CN$ ,  $-NCS$ ,  $-CF_3$ ,  $-OCF_3$ ,  $=O$ ,  $OH$ ,  $-CO_2H$ ,  
 $-CO_2R^{11}$ ,  $C(=O)NR^{11}R^{11a}$ ,  $NHC(=O)R^{11}$ ,  
 $-NR^{11}R^{11a}$ ,  $OR^{11a}$ ,  $SR^{11a}$ ,  $C(=O)R^{11a}$ ,  $S(=O)R^{11a}$ ,  
 $-SO_2R^{11}$ ,  $SO_2NR^{11}R^{11a}$ ,  $C_1-C_4$ -alkyl,  $C_1-C_4$ -alkoxy,  
 $C_1-C_4$ -haloalkyl,  $C_1-C_4$ -haloalkoxy, phenyl, and benzyl,

$R^8$  is  $H$  or  $C_1-C_4$ -alkyl;

$R^{9a}$  is selected from the group:  $H$ ,  $-S(=O)R^{9b}$ ,  $-S(=O)_2R^{9b}$ ,

$-S(=O)_2NHR^{9b}$ ,  $-C(=O)R^{9b}$ ,  $-C(=O)OR^{9b}$ ,  $-C(=O)NHR^{9b}$ ,  
 $-C(=O)NHC(=O)R^{9b}$ ;

$C_1-C_6$  alkyl substituted with 0-3  $R^{9c}$ ;

$C_2-C_6$  alkenyl substituted with 0-3  $R^{9c}$ ;

$C_2-C_6$  alkynyl substituted with 0-3  $R^{9c}$ ;

$C_3-C_6$  cycloalkyl substituted with 0-3  $R^{9d}$ ;

$C_3-C_{14}$  carbocycle substituted with 0-4  $R^{9d}$ ;

aryl substituted with 0-5  $R^{9d}$ ; and

~~5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, optionally saturated, partially unsaturated or unsaturated;~~

~~and said 5-10 membered heterocyclic group is substituted with 0-4 R<sup>9d</sup>,~~

R<sup>9b</sup> is selected from the group: H;

C<sub>1</sub>-C<sub>6</sub> alkyl substituted with 0-3 R<sup>9c</sup>;

C<sub>2</sub>-C<sub>6</sub> alkenyl substituted with 0-3 R<sup>9c</sup>;

C<sub>2</sub>-C<sub>6</sub> alkynyl substituted with 0-3 R<sup>9c</sup>;

C<sub>3</sub>-C<sub>6</sub> cycloalkyl substituted with 0-3 R<sup>9d</sup>;

C<sub>3</sub>-C<sub>14</sub> carbocycle substituted with 0-4 R<sup>9d</sup>; and

aryl substituted with 0-5 R<sup>9d</sup>; and

~~5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N; optionally saturated, partially unsaturated or unsaturated,~~

~~and said 5-10 membered heterocyclic group is substituted with 0-4 R<sup>9d</sup>,~~

R<sup>9c</sup> is selected from the group: CF<sub>3</sub>, OCF<sub>3</sub>, Cl, F, Br, I, =O, OH,

C(=O)OR<sup>11</sup>, NH<sub>2</sub>, NH(CH<sub>3</sub>), N(CH<sub>3</sub>)<sub>2</sub>, CN, NO<sub>2</sub>,

C<sub>1</sub>-C<sub>6</sub> alkyl substituted with 0-3 R<sup>9d</sup>;

C<sub>2</sub>-C<sub>6</sub> alkenyl substituted with 0-3 R<sup>9d</sup>;

C<sub>2</sub>-C<sub>6</sub> alkynyl substituted with 0-3 R<sup>9d</sup>;

C<sub>3</sub>-C<sub>6</sub> cycloalkyl substituted with 0-3 R<sup>9e</sup>;

C<sub>3</sub>-C<sub>14</sub> carbocycle substituted with 0-4 R<sup>9e</sup>; and

aryl substituted with 0-5 R<sup>9e</sup>; and

~~5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N; optionally saturated, partially unsaturated or unsaturated,~~

~~and said 5-10 membered heterocyclic group is substituted with 0-4 R<sup>9e</sup>,~~

and said 5-10 membered heterocyclic group is substituted with 0-4 R<sup>9e</sup>;

R<sup>9d</sup> is selected at each occurrence from the group:

CF<sub>3</sub>, OCF<sub>3</sub>, Cl, F, Br, I, =O, OH, C(O)OR<sup>11</sup>, NH<sub>2</sub>, NH(CH<sub>3</sub>), N(CH<sub>3</sub>)<sub>2</sub>, CN, NO<sub>2</sub>;

C<sub>1</sub>-C<sub>4</sub> alkyl substituted with 0-3 R<sup>9e</sup>;

C<sub>1</sub>-C<sub>4</sub> alkoxy substituted with 0-3 R<sup>9e</sup>;

C<sub>3</sub>-C<sub>6</sub> cycloalkyl substituted with 0-3 R<sup>9e</sup>; and

aryl substituted with 0-5 R<sup>9e</sup>; and

5-6 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, optionally saturated, partially unsaturated or unsaturated; and said 5-6 membered heterocyclic group is substituted with 0-4 R<sup>9e</sup>;

R<sup>9e</sup> is selected at each occurrence from the group:

C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, CF<sub>3</sub>, OCF<sub>3</sub>, Cl, F, Br, I, =O, OH, phenyl, C(O)OR<sup>11</sup>, NH<sub>2</sub>, NH(CH<sub>3</sub>), N(CH<sub>3</sub>)<sub>2</sub>, -CN, and NO<sub>2</sub>;

R<sup>10</sup> is selected from the group: CO<sub>2</sub>R<sup>11</sup>, NR<sup>11</sup>R<sup>11a</sup>, and C<sub>1</sub>-C<sub>6</sub> alkyl substituted with 0-1 R<sup>10a</sup>;

R<sup>10a</sup> is selected from the group: halo, NO<sub>2</sub>, CN, CF<sub>3</sub>, -CO<sub>2</sub>R<sup>11</sup>, NR<sup>11</sup>R<sup>11a</sup>, OR<sup>11</sup>, SR<sup>11</sup>, C(=NH)NH<sub>2</sub>, and aryl substituted with 0-1 R<sup>10b</sup>;

$R^{10b}$  is selected from the group:  $CO_2H$ ,  $NH_2$ ,  $OH$ ,  $SH$ , and  
 $C(=NH)NH_2+$

$R^{10e}$  is H or  $C_1-C_4$  alkyl;

alternatively,  $R^{10}$  and  $R^{10e}$  can be combined to form a  $C_3-C_6$  cycloalkyl group substituted with 0-1  $R^{10a}$ ,

$R^{11}$  and  $R^{11a}$  are, at each occurrence, independently selected from the group: H;

$C_1-C_6$  alkyl substituted with 0-3  $R^{11b}$ ;

$C_2-C_6$  alkaryl substituted with 0-3  $R^{11b}$ ;

$C_2-C_6$  alkynyl substituted with 0-3  $R^{11b}$ ;

$C_3-C_7$  cycloalkyl substituted with 0-3  $R^{11b}$ ;

aryl substituted with 0-3  $R^{11b}$ ; and

aryl( $C_1-C_4$  alkyl)- substituted with 0-3  $R^{11b}$ ;

$R^{11b}$  is OH,  $C_1-C_4$  alkoxy, F, Cl, Br, I,  $NH_2$ , or  $-NH(C_1-C_4$  alkyl);

$R^{12}$  is H or  $C_1-C_4$  alkyl;

$R^{14}$  is  $C_1-C_4$  alkyl or  $C_2-C_4$  alkaryl;

$R^{19}$  and  $R^{19a}$  are independently selected from the group: H,  $C_1-C_4$  alkyl,  $C_1-C_4$  haloalkyl, aryl, aryl( $C_1-C_4$  alkyl),  $C_3-C_6$  cycloalkyl, and  $C_3-C_6$  cycloalkyl( $C_1-C_4$  alkyl);

alternatively,  $\text{NR}^{19}\text{R}^{19a}$  may form a 5-6 membered heterocyclic group consisting of carbon atoms, a nitrogen atom, and optionally a second heteroatom selected from the group: O, S, and N;

$\text{R}^{20}$  and  $\text{R}^{20a}$  are independently selected from the group: H,  $\text{C}_1\text{-}\text{C}_4$  alkyl,  $\text{C}_1\text{-}\text{C}_4$  haloalkyl, aryl, aryl( $\text{C}_1\text{-}\text{C}_4$  alkyl),  $\text{C}_3\text{-}\text{C}_6$  cycloalkyl, and  $\text{C}_3\text{-}\text{C}_6$  cycloalkyl( $\text{C}_1\text{-}\text{C}_4$  alkyl);

alternatively,  $\text{NR}^{20}\text{R}^{20a}$  may form a 5-6 membered heterocyclic group consisting of carbon atoms, a nitrogen atom, and optionally a second heteroatom selected from the group: O, S, and N;

$\text{OR}^{26}$  and  $\text{OR}^{27}$  are independently selected from:

- a) -OH,
- b) -F,
- c)  $\text{NR}^{28}\text{R}^{29}$ ,
- d)  $\text{C}_1\text{-}\text{C}_8$  alkoxy, and

when taken together,  $\text{OR}^{26}$  and  $\text{OR}^{27}$  form:

- e) a cyclic boronic ester where said cyclic boronic ester contains from 2 to 20 carbon atoms, and, optionally, 1, 2, or 3 heteroatoms which can be N, S, or O; and
- f) a cyclic boronic amide where said boronic amide contains from 2 to 20 carbon atoms and, optionally, 1, 2, or 3 heteroatoms which can be N, S, or O; or
- g) a cyclic boronic amide ester where said boronic amide ester contains from 2 to 20 carbon atoms and, optionally, 1, 2, or 3 heteroatoms which can be N, S, or O;

R<sup>28</sup> and R<sup>29</sup>, are independently selected from: H, C<sub>1</sub>-C<sub>4</sub>-alkyl, ary1(C<sub>1</sub>-C<sub>4</sub>-alkyl), and C<sub>3</sub>-C<sub>7</sub>-cycloalkyl;

A<sup>3</sup>, A<sup>4</sup>, A<sup>5</sup>, A<sup>6</sup>, A<sup>7</sup>, A<sup>8</sup>, and A<sup>9</sup> are independently selected from an amino acid residue; and

an amino acid residue, at each occurrence, independently comprises a natural amino acid, a modified amino acid or an unnatural amino acid wherein said natural, modified or unnatural amino acid is of either D or L configuration. is valine.

2. (currently amended) A compound of Claim 1, or a stereoisomer, or a pharmaceutically acceptable salt form or prodrug thereof, wherein:

A<sup>1</sup> is -CH<sub>2</sub>- or CH<sub>2</sub>CH<sub>2</sub>-;

A<sup>2</sup> is C(=O)R<sup>9b</sup>, S(=O)R<sup>9b</sup>, S(=O)<sub>2</sub>R<sup>9b</sup>, CONHR<sup>9b</sup>,  
S(=O)<sub>2</sub>NHR<sup>9b</sup>, C(=O)OR<sup>9b</sup>,  
A<sup>3</sup>-R<sup>9a</sup>,  
A<sup>3</sup>-A<sup>4</sup>-R<sup>9a</sup>,  
A<sup>3</sup>-A<sup>4</sup>-A<sup>5</sup>-R<sup>9a</sup>, or  
A<sup>3</sup>-A<sup>4</sup>-A<sup>5</sup>-A<sup>6</sup>-R<sup>9a</sup>,

W is selected from the group:

-B(OR<sup>26</sup>)(OR<sup>27</sup>),  
-C(=O)C(=O)Q,  
-C(=O)C(=O)NHQ,  
-C(=O)C(=O)OQ,

$\text{C}(=\text{O})\text{CF}_2\text{C}(=\text{O})\text{NH-Q}$ ,  
 $\text{C}(=\text{O})\text{CF}_3$ ,  
 $\text{C}(=\text{O})\text{CF}_2\text{CF}_3$ ,  
 $\text{C}(=\text{O})\text{H}$ , and  
 $\text{C}(=\text{O})\text{W}^1$ ,

$\text{W}^1$  is  $\text{OR}^8$  or  $\text{NR}^{11}\text{R}^{11a}$ ,

$\text{Q}$  is selected from the group:

$(\text{CR}^{10}\text{R}^{10e})_m\text{Q}^1$ ,  
 $\text{C}_1\text{--C}_4$  alkyl substituted with  $\text{Q}^1$ ,  
 $\text{C}_2\text{--C}_4$  alkenyl substituted with  $\text{Q}^1$ , and  
 $\text{C}_2\text{--C}_4$  alkynyl substituted with  $\text{Q}^1$ ,

$m$  is 1 or 2;

$\text{Q}^1$  is selected from the group:

$\text{CO}_2\text{R}^{11}$ ,  $\text{SO}_2\text{R}^{11}$ ,  $\text{SO}_3\text{R}^{11}$ ,  $\text{P}(\text{O})_2\text{R}^{11}$ ,  $\text{P}(\text{O})_3\text{R}^{11}$ ,  
phenyl substituted with 0-4  $\text{Q}^{1a}$ , and  
5-6 membered heterocyclic group consisting of carbon atoms and  
1-4 heteroatoms selected from the group: O, S, and N,  
optionally saturated, partially unsaturated or unsaturated,  
and said 5-6 membered heterocyclic group is substituted  
with 0-4  $\text{Q}^{1a}$ ,

$\text{Q}^{1a}$  is H, F, Cl, Br, I,  $\text{NO}_2$ , CN, NCS,  $\text{CF}_3$ ,  $\text{OCF}_3$ ,  
 $\text{CO}_2\text{R}^{19}$ ,  $\text{C}(=\text{O})\text{NR}^{19}\text{R}^{19a}$ ,  $\text{NHC}(=\text{O})\text{R}^{19}$ ,  $\text{SO}_2\text{R}^{19}$ ,  
 $\text{SO}_2\text{NR}^{19}\text{R}^{19a}$ ,  $\text{NR}^{19}\text{R}^{19a}$ ,  $\text{OR}^{19}$ ,  $\text{SR}^{19}$ ,  $\text{C}_1\text{--C}_4$  alkyl,

~~C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl, or C<sub>1</sub>-C<sub>4</sub> haloalkoxy,~~

R<sup>1</sup> is selected from the group: H, F,

~~C<sub>1</sub>-C<sub>6</sub> alkyl substituted with 0-3 R<sup>1a</sup>;~~

~~C<sub>2</sub>-C<sub>6</sub> alkenyl substituted with 0-3 R<sup>1a</sup>; and~~

~~C<sub>2</sub>-C<sub>6</sub> alkynyl substituted with 0-3 R<sup>1a</sup>; and~~

~~C<sub>3</sub>-C<sub>6</sub> cycloalkyl substituted with 0-3 R<sup>1a</sup>,~~

~~R<sup>1a</sup> is selected at each occurrence from the group:~~

~~C<sub>1</sub>, F, Br, I, CF<sub>3</sub>, CHF<sub>2</sub>, OH, =O, SH, CO<sub>2</sub>R<sup>1b</sup>, SO<sub>2</sub>R<sup>1b</sup>,~~

~~SO<sub>3</sub>R<sup>1b</sup>, P(O)<sub>2</sub>R<sup>1b</sup>, P(O)<sub>3</sub>R<sup>1b</sup>, C(=O)NHR<sup>1b</sup>,~~

~~NHC(=O)R<sup>1b</sup>, SO<sub>2</sub>NHR<sup>1b</sup>, OR<sup>1b</sup>, SR<sup>1b</sup>, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, S(C<sub>1</sub>-C<sub>6</sub> alkyl);~~

~~C<sub>1</sub>-C<sub>4</sub> alkyl substituted with 0-3 R<sup>1c</sup>,~~

~~aryl substituted with 0-5 R<sup>1c</sup>,~~

~~O(CH<sub>2</sub>)<sub>n</sub> aryl substituted with 0-5 R<sup>1c</sup>,~~

~~S(CH<sub>2</sub>)<sub>n</sub> aryl substituted with 0-5 R<sup>1c</sup>, and~~

~~5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, optionally saturated, partially unsaturated or unsaturated, and said 5-10 membered heterocyclic group is substituted with 0-3 R<sup>1c</sup>,~~

~~n is 0, 1 or 2;~~

~~R<sup>1b</sup> is H,~~

~~C<sub>1</sub>-C<sub>4</sub> alkyl substituted with 0-3 R<sup>1c</sup>,~~

$\text{C}_2\text{-C}_4$  alkenyl substituted with 0-3  $\text{R}^{1e}$ ;

$\text{C}_2\text{-C}_4$  alkynyl substituted with 0-3  $\text{R}^{1e}$ ;

$\text{C}_3\text{-C}_6$  cycloalkyl substituted with 0-5  $\text{R}^{1e}$ ;

aryl substituted with 0-5  $\text{R}^{1e}$ ;

aryl  $\text{C}_1\text{-C}_4$  alkyl substituted with 0-4  $\text{R}^{1e}$ ; or

5-6 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N; optionally saturated, partially unsaturated or unsaturated, and said 5-10 membered heterocyclic group is substituted with 0-4  $\text{R}^{1e}$ ;

$\text{R}^{1e}$  is selected at each occurrence from the group:

$\text{C}_1\text{-C}_4$  alkyl, Cl, F, Br, I, OH, SH, CN,  $\text{NO}_2$ ,  $\text{OR}^{1d}$ ,  $\text{C}(-\text{O})\text{OR}^{1d}$ ,  $\text{NR}^{1d}\text{R}^{1d}$ ,  $\text{SO}_2\text{R}^{1d}$ ,  $\text{SO}_3\text{R}^{1d}$ ,  $\text{C}(-\text{O})\text{NHR}^{1d}$ ,  $\text{NHC}(-\text{O})\text{R}^{1d}$ ,  $\text{SO}_2\text{NHR}^{1d}$ ,  $\text{CF}_3$ ,  $\text{OCF}_3$ ,  $\text{C}_3\text{-C}_6$  cycloalkyl, phenyl, and benzyl;

$\text{R}^{1d}$  is selected at each occurrence from the group: H,  $\text{C}_1\text{-C}_4$  alkyl, phenyl and benzyl;

$\text{R}^2$  is selected from the group: H,  $\text{C}_1\text{-C}_4$  alkyl,  $\text{C}_2\text{-C}_4$  alkenyl,  $\text{C}_2\text{-C}_4$  alkynyl,  $\text{C}_3\text{-C}_4$  cycloalkyl, and  $\text{C}_3\text{-C}_4$  cycloalkyl( $\text{C}_1\text{-C}_4$  alkyl);

alternatively,  $\text{R}^1$  and  $\text{R}^2$  can be combined to form a 4-7 membered cyclic group consisting of carbon atoms; substituted with 0-2  $\text{R}^{14}$ ;

$\text{R}^3$  is selected from the group:  $\text{R}^4$ ,

$-(CH_2)_p-NH-R^4$ ,  
 $-(CH_2)_p-NHC(=O)-R^4$ ,  
 $-(CH_2)_p-C(=O)NH-R^4$ ,  
 $-(CH_2)_p-C(=O)O-R^4$ ,  
 $-(CH_2)_p-C(=O)C(=O)-R^4$ ,  
 $-(CH_2)_p-C(=O)C(=O)NH-R^4$ ,  
 $-(CH_2)_p-NHC(=O)NH-R^4$ ,  
 $-(CH_2)_p-NHC(=O)NHC(=O)-R^4$ ,  
 $-(CH_2)_p-NHS(=O)_2-R^4$ ,  
 $-(CH_2)_p-S(=O)_2NH-R^4$ ,  
 $-(CH_2)_p-C(=O)-R^4$ ,  
 $-(CH_2)_p-O-R^4$ , and  
 $-(CH_2)_p-S-R^4$ ,

$C_1-C_6$  alkyl substituted with phenyl,

$C_1-C_6$  alkenyl substituted with phenyl,

$-CH_2CONHPh$ , and

(2-phenylquinolin-4-yl)methyl;

$p$  is 0, 1, or 2;

$R^4$  is selected from the group:

~~$C_1-C_6$  alkyl substituted with 0-3  $R^{4a}$ ,~~  
 ~~$C_2-C_6$  alkenyl substituted with 0-3  $R^{4a}$ ,~~  
 ~~$C_2-C_6$  alkynyl substituted with 0-3  $R^{4a}$ ,~~  
 ~~$C_3-C_{10}$  cycloalkyl substituted with 0-4  $R^{4b}$ ,~~  
 ~~$C_3-C_{10}$  carbocycle substituted with 0-4  $R^{4b}$ ,~~  
~~aryl substituted with 0-5  $R^{4b}$ ,~~

~~aryl- $C_1-C_4$  alkyl substituted with 0-5  $R^{4b}$ , and~~  
~~5-10 membered heterocyclic group consisting of carbon atoms~~  
~~and 1-4 heteroatoms selected from the group: O, S, and N,~~  
~~optionally saturated, partially unsaturated or~~  
~~unsaturated; and said 5-10 membered heterocyclic group is~~  
~~substituted with 0-3  $R^{4b}$ ,~~

$R^{4a}$  is, at each occurrence, independently selected from:

~~H, F, Cl, Br, I, NO<sub>2</sub>, CN, NCS, CF<sub>3</sub>, OCF<sub>3</sub>,~~  
~~=O, OH, CO<sub>2</sub>H, C(=NH)NH<sub>2</sub>, CO<sub>2</sub>R<sup>11</sup>, C(=O)NR<sup>11</sup>R<sup>11a</sup>,~~  
~~-NHC(=O)R<sup>11</sup>, NR<sup>11</sup>R<sup>11a</sup>, OR<sup>11a</sup>, SR<sup>11a</sup>, C(=O)R<sup>11a</sup>,~~  
~~S(=O)R<sup>11a</sup>, SO<sub>2</sub>R<sup>11</sup>, SO<sub>2</sub>NR<sup>11</sup>R<sup>11a</sup>, NHC(=NH)NHR<sup>11</sup>,~~  
~~C(=NH)NHR<sup>11</sup>, NOR<sup>11</sup>, NR<sup>11</sup>C(=O)OR<sup>11a</sup>,~~  
~~NR<sup>11</sup>C(=O)NR<sup>11</sup>R<sup>11a</sup>, NR<sup>11</sup>SO<sub>2</sub>NR<sup>11</sup>R<sup>11a</sup>, NR<sup>11</sup>SO<sub>2</sub>R<sup>11a</sup>,~~  
~~-OP(O)(OR<sup>11</sup>)<sub>2</sub>,~~

~~$C_1-C_4$  alkyl substituted with 0-3  $R^{4b}$ ,~~

~~$C_2-C_4$  alkenyl substituted with 0-3  $R^{4b}$ ,~~

~~$C_2-C_4$  alkynyl substituted with 0-3  $R^{4b}$ ,~~

~~$C_3-C_7$  cycloalkyl substituted with 0-4  $R^{4e}$ ,~~

~~$C_3-C_{10}$  carbocycle substituted with 0-4  $R^{4e}$ ,~~

~~aryl substituted with 0-5  $R^{4e}$ , and~~

~~5-10 membered heterocyclic group consisting of carbon atoms~~  
~~and 1-4 heteroatoms selected from the group: O, S, and N,~~  
~~optionally saturated, partially unsaturated or~~  
~~unsaturated; and said 5-10 membered heterocyclic group is~~  
~~substituted with 0-3  $R^{4e}$ ,~~

$R^{4b}$  is, at each occurrence, independently selected from:

~~H, F, Cl, Br, I, NO<sub>2</sub>, CN, NCS, CF<sub>3</sub>, OCF<sub>3</sub>, =O, OH, CO<sub>2</sub>H,~~  
~~-C(=NH)NH<sub>2</sub>, CO<sub>2</sub>R<sup>11</sup>, C(=O)NR<sup>11</sup>R<sup>11a</sup>,~~  
~~-NHC(=O)R<sup>11</sup>, NR<sup>11</sup>R<sup>11a</sup>, OR<sup>11a</sup>, SR<sup>11a</sup>, C(=O)R<sup>11a</sup>,~~  
~~-S(=O)R<sup>11a</sup>, SO<sub>2</sub>R<sup>11</sup>, SO<sub>2</sub>NR<sup>11</sup>R<sup>11a</sup>, NHC(=NH)NHR<sup>11</sup>,~~  
~~-C(=NH)NHR<sup>11</sup>, =NOR<sup>11</sup>, NR<sup>11</sup>C(=O)OR<sup>11a</sup>,~~  
~~-OC(=O)NR<sup>11</sup>R<sup>11a</sup>, NR<sup>11</sup>C(=O)NR<sup>11</sup>R<sup>11a</sup>, NR<sup>11</sup>SO<sub>2</sub>NR<sup>11</sup>R<sup>11a</sup>,~~  
~~NR<sup>11</sup>SO<sub>2</sub>R<sup>11a</sup>, OP(O)(OR<sup>11</sup>)<sub>2</sub>,~~  
~~ε<sub>1</sub>-ε<sub>4</sub>-alkyl substituted with 0-3 R<sup>4e</sup>,~~  
~~ε<sub>2</sub>-ε<sub>4</sub>-alkenyl substituted with 0-3 R<sup>4e</sup>,~~  
~~ε<sub>2</sub>-ε<sub>4</sub>-alkynyl substituted with 0-3 R<sup>4e</sup>,~~  
~~ε<sub>3</sub>-ε<sub>6</sub>-cycloalkyl substituted with 0-4 R<sup>4d</sup>,~~  
~~aryl substituted with 0-5 R<sup>4d</sup>, and~~  
~~5-10 membered heterocyclic group consisting of carbon atoms~~  
~~and 1-4 heteroatoms selected from the group: O, S, and N,~~  
~~optionally saturated or unsaturated; and said 5-10~~  
~~membered heterocyclic group is substituted with 0-3 R<sup>4d</sup>,~~

R<sup>4e</sup> is, at each occurrence, independently selected from:

~~H, F, Cl, Br, I, NO<sub>2</sub>, CN, NCS, CF<sub>3</sub>, OCF<sub>3</sub>, =O, OH, CO<sub>2</sub>H,~~  
~~-C(=NH)NH<sub>2</sub>, CO<sub>2</sub>R<sup>11</sup>, C(=O)NR<sup>11</sup>R<sup>11a</sup>,~~  
~~-NHC(=O)R<sup>11</sup>, NR<sup>11</sup>R<sup>11a</sup>, OR<sup>11a</sup>, SR<sup>11a</sup>, C(=O)R<sup>11a</sup>,~~  
~~-S(=O)R<sup>11a</sup>, SO<sub>2</sub>R<sup>11</sup>, SO<sub>2</sub>NR<sup>11</sup>R<sup>11a</sup>,~~  
~~ε<sub>1</sub>-ε<sub>4</sub>-haloalkyl, ε<sub>1</sub>-ε<sub>4</sub>-haloalkoxy,~~  
~~ε<sub>1</sub>-ε<sub>4</sub>-alkyl substituted with 0-3 R<sup>4d</sup>,~~  
~~ε<sub>2</sub>-ε<sub>4</sub>-alkenyl substituted with 0-3 R<sup>4d</sup>,~~  
~~ε<sub>2</sub>-ε<sub>4</sub>-alkynyl substituted with 0-3 R<sup>4d</sup>,~~  
~~ε<sub>3</sub>-ε<sub>6</sub>-cycloalkyl substituted with 0-4 R<sup>4d</sup>,~~

aryl substituted with 0-5  $R^{4d}$ , and  
 5-10 membered heterocyclic group consisting of carbon atoms  
 and 1-4 heteroatoms selected from the group: O, S, and N,  
 optionally saturated or unsaturated; and said 5-10  
 membered heterocyclic group is substituted with 0-3  $R^{4d}$ ,

$R^{4d}$  is, at each occurrence, independently selected from:

H, F, Cl, Br, I, NO<sub>2</sub>, CN, NCS, CF<sub>3</sub>, OCF<sub>3</sub>, =O, OH, CO<sub>2</sub>H,  
 CO<sub>2</sub>R<sup>11</sup>, C(=O)NR<sup>11</sup>R<sup>11a</sup>, NHC(=O)R<sup>11</sup>,  
 NR<sup>11</sup>R<sup>11a</sup>, OR<sup>11a</sup>, SR<sup>11a</sup>, C(=O)R<sup>11a</sup>, S(=O)R<sup>11a</sup>,  
 SO<sub>2</sub>R<sup>11</sup>, SO<sub>2</sub>NR<sup>11</sup>R<sup>11a</sup>, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy,  
 C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> haloalkoxy, phenyl, and benzyl,

$R^8$  is H or C<sub>1</sub>-C<sub>4</sub> alkyl;

$R^{9a}$  is selected from the group: H, S(=O)R<sup>9b</sup>, S(=O)<sub>2</sub>R<sup>9b</sup>,

S(=O)<sub>2</sub>NHR<sup>9b</sup>, C(=O)R<sup>9b</sup>, C(=O)OR<sup>9b</sup>, C(=O)NHR<sup>9b</sup>,  
 C(=O)NHC(=O)R<sup>9b</sup>,

C<sub>1</sub>-C<sub>6</sub> alkyl substituted with 0-3  $R^{9c}$ ,

C<sub>2</sub>-C<sub>6</sub> alkenyl substituted with 0-3  $R^{9c}$ ,

C<sub>2</sub>-C<sub>6</sub> alkynyl substituted with 0-3  $R^{9c}$ ,

C<sub>3</sub>-C<sub>6</sub> cycloalkyl substituted with 0-3  $R^{9d}$ ,

C<sub>3</sub>-C<sub>14</sub> carbocycle substituted with 0-4  $R^{9d}$ ,

aryl substituted with 0-5  $R^{9d}$ , and

5-10 membered heterocyclic group consisting of carbon atoms  
 and 1-4 heteroatoms selected from the group: O, S, and N,  
 optionally saturated, partially unsaturated or unsaturated;

and said 5-10 membered heterocyclic group is substituted with 0-4  $R^{9d}$ ,

$R^{9b}$  is selected from the group: H,

$\epsilon_1$ - $\epsilon_6$  alkyl substituted with 0-3  $R^{9e}$ ,

$\epsilon_2$ - $\epsilon_6$  alkenyl substituted with 0-3  $R^{9e}$ ,

$\epsilon_2$ - $\epsilon_6$  alkynyl substituted with 0-3  $R^{9e}$ ,

$\epsilon_3$ - $\epsilon_6$  cycloalkyl substituted with 0-3  $R^{9d}$ ,

$\epsilon_3$ - $\epsilon_{14}$  carboecycle substituted with 0-4  $R^{9d}$ ,

aryl substituted with 0-5  $R^{9d}$ , and

5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, optionally saturated, partially unsaturated or unsaturated, and said 5-10 membered heterocyclic group is substituted with 0-4  $R^{9d}$ ,

$R^{9e}$  is selected from the group:  $CF_3$ ,  $OCF_3$ ,  $Cl$ ,  $F$ ,  $Br$ ,  $I$ ,  $=O$ ,  $OH$ ,

$C(O)OR^{11}$ ,  $NH_2$ ,  $NH(CH_3)$ ,  $N(CH_3)_2$ ,  $CN$ ,  $NO_2$ ,

$\epsilon_1$ - $\epsilon_6$  alkyl substituted with 0-3  $R^{9d}$ ,

$\epsilon_2$ - $\epsilon_6$  alkenyl substituted with 0-3  $R^{9d}$ ,

$\epsilon_2$ - $\epsilon_6$  alkynyl substituted with 0-3  $R^{9d}$ ,

$\epsilon_3$ - $\epsilon_6$  cycloalkyl substituted with 0-3  $R^{9e}$ ,

$\epsilon_3$ - $\epsilon_{14}$  carboecycle substituted with 0-4  $R^{9e}$ ,

aryl substituted with 0-5  $R^{9e}$ , and

5-10 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, optionally saturated, partially unsaturated or unsaturated,

and said 5-10 membered heterocyclic group is substituted with 0-4  $R^{9e}$ ,

$R^{9d}$  is selected at each occurrence from the group:

$CF_3$ ,  $OCF_3$ ,  $Cl$ ,  $F$ ,  $Br$ ,  $I$ ,  $=O$ ,  $OH$ ,  $C(O)OR^{11}$ ,  $NH_2$ ,  $NH(CH_3)$ ,

$N(CH_3)_2$ ,  $CN$ ,  $NO_2$ ,

$C_1-C_4$  alkyl substituted with 0-3  $R^{9e}$ ,

$C_1-C_4$  alkoxy substituted with 0-3  $R^{9e}$ ,

$C_3-C_6$  cycloalkyl substituted with 0-3  $R^{9e}$ ,

aryl substituted with 0-5  $R^{9e}$ ; and

5-6 membered heterocyclic group consisting of carbon atoms and 1-4 heteroatoms selected from the group:  $O$ ,  $S$ , and  $N$ , optionally saturated, partially unsaturated or unsaturated; and said 5-6 membered heterocyclic group is substituted with 0-4  $R^{9e}$ ,

$R^{9e}$  is selected at each occurrence from the group:

$C_1-C_4$  alkyl,  $C_1-C_4$  alkoxy,  $CF_3$ ,  $OCF_3$ ,  $Cl$ ,  $F$ ,  $Br$ ,  $I$ ,  $=O$ ,  $OH$ ,

phenyl,  $C(O)OR^{11}$ ,  $NH_2$ ,  $NH(CH_3)$ ,  $N(CH_3)_2$ ,  $CN$ , and  $NO_2$ ,

$R^{10}$  is selected from the group:  $CO_2R^{11}$ ,  $NR^{11}R^{11a}$ , and  $C_1-C_6$  alkyl substituted with 0-1  $R^{10a}$ ,

$R^{10a}$  is selected from the group: halo,  $NO_2$ ,  $CN$ ,  $CF_3$ ,

$-CO_2R^{11}$ ,  $NR^{11}R^{11a}$ ,  $OR^{11}$ ,  $SR^{11}$ ,  $C(=NH)NH_2$ , and aryl

substituted with 0-1  $R^{10b}$ ,

$R^{10b}$  is selected from the group:  $CO_2H$ ,  $NH_2$ ,  $OH$ ,  $SH$ , and  
 $C(=NH)NH_2$ ,

$R^{10e}$  is H or  $C_1-C_4$  alkyl;

alternatively,  $R^{10}$  and  $R^{10e}$  can be combined to form a  $C_3-C_6$  cycloalkyl group substituted with 0-1  $R^{10a}$ ,

$R^{11}$  and  $R^{11a}$  are, at each occurrence, independently selected from the group: H;

$C_1-C_6$  alkyl substituted with 0-3  $R^{11b}$ ,

$C_2-C_6$  alkenyl substituted with 0-3  $R^{11b}$ ,

$C_2-C_6$  alkynyl substituted with 0-3  $R^{11b}$ ,

$C_3-C_7$  cycloalkyl substituted with 0-3  $R^{11b}$ ,

aryl substituted with 0-3  $R^{11b}$ ; and

aryl( $C_1-C_4$  alkyl) substituted with 0-3  $R^{11b}$ ,

$R^{11b}$  is OH,  $C_1-C_4$  alkoxy, F, Cl, Br, I,  $NH_2$ , or  $NH(C_1-C_4$  alkyl);

$R^{12}$  is H or  $C_1-C_4$  alkyl;

$R^{14}$  is  $C_1-C_4$  alkyl or  $C_2-C_4$  alkenyl;

$R^{19}$  and  $R^{19a}$  are independently selected from the group: H,  $C_1-C_4$  alkyl,  $C_1-C_4$  haloalkyl, aryl, aryl( $C_1-C_4$  alkyl),  $C_3-C_6$  cycloalkyl, and  $C_3-C_6$  cycloalkyl( $C_1-C_4$  alkyl);

alternatively,  $NR^{19}R^{19a}$  may form a 5-6 membered heterocyclic group consisting of carbon atoms, a nitrogen atom, and optionally a second heteroatom selected from the group: O, S, and N;

and

$OR^{26}$  and  $OR^{27}$  are independently selected from:

- a)  $OH$ ,
- b)  $F$ ,
- c)  $NR^{28}R^{29}$ ,
- d)  $C_1-C_8$  alkoxy, and

when taken together,  $OR^{26}$  and  $OR^{27}$  form:

- e) a cyclic boronic ester where said cyclic boronic ester contains from 2 to 20 carbon atoms, and, optionally, 1, 2, or 3 heteroatoms which can be N, S, or O pinanediol.,

$R^{28}$  and  $R^{29}$ , are independently selected from: H,  $C_1-C_4$  alkyl, aryl ( $C_1-C_4$  alkyl), and  $C_3-C_7$  cycloalkyl;

$A^3$ ,  $A^4$ ,  $A^5$ , and  $A^6$ , are independently selected from an amino acid residue; and

an amino acid residue, at each occurrence, independently comprises a natural amino acid, a modified amino acid or an unnatural amino acid wherein said natural, modified or unnatural amino acid is of either D or L configuration.

3. (canceled)

4. (canceled)

5. (canceled)

6. (canceled)

7. (currently amended) A compound of Claim 1, or a stereoisomer or a pharmaceutically acceptable salt form ~~or prodrug~~ thereof, selected from:— the group consisting of

(4*S*)-*N*-{[(1*R*)-1-[(3*αS*,4*S*,6*S*,7*αR*)-hexahydro-3*α*,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl}-3-{(2*S*)-3-methyl-2-[(phenylacetyl)-amino]-butanoyl}-2-oxo-1-(3-phenylpropyl)-4-imidazolidinecarboxamide;

*tert*-butyl (1*S*)-*N*-{[(1*R*)-1-[(3*αS*,4*S*,6*S*,7*αR*)-hexahydro-3*α*,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl}amino)carbonyl]-2-oxo-3-(3-phenylpropyl)imidazolidinyl]carbonyl}-2-methylpropylcarbamate;

(4*S*)-*N*-{[(1*R*)-1-[(3*αS*,4*S*,6*S*,7*αR*)-hexahydro-3*α*,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl}-3-{(2*S*)-2-[(anilinocarbonyl)amino]-3-methylbutanoyl}-2-oxo-1-(3-phenylpropyl)-4-imidazolidinecarboxamide;

(4*S*)-*N*-{[(1*R*)-1-[(3*αS*,4*S*,6*S*,7*αR*)-hexahydro-3*α*,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl}-3-{(2*S*)-2-[(9*H*-fluoren-1-ylcarbonyl)amino]-3-methylbutanoyl}-2-oxo-1-(3-phenylpropyl)-4-imidazolidinecarboxamide;

(4*S*)-*N*-{[(1*R*)-1-[(3*αS*,4*S*,6*S*,7*αR*)-hexahydro-3*α*,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl}-3-{(2*S*)-2-[(4-

methoxyphenyl)acetyl]amino}-3-methylbutanoyl)-2-oxo-1-(3-phenylpropyl)-4-imidazolidinecarboxamide;

(4*S*)-*N*-{[(1*R*)-1-[(3*αS*,4*S*,6*S*,7*αR*)-hexahydro-3*α*,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-butenyl}-3-{(2*S*)-2-[(9*H*-fluoren-1-ylcarbonyl)amino]-3-methylbutanoyl}-2-oxo-1-(3-phenylpropyl)-4-imidazolidinecarboxamide;

9*H*-fluoren-9-ylmethyl (1*S*)-*N*-{[(1*R*)-1-[(3*αS*,4*S*,6*S*,7*αR*)-hexahydro-3*α*,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl}amino]carbonyl]-2-oxo-3-(3-phenylpropyl)imidazolidinyl]carbonyl}-2-methylpropylcarbamate;

(4*S*)-*N*-{[(1*R*)-1-[(3*αS*,4*S*,6*S*,7*αR*)-hexahydro-3*α*,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl}-3-{(2*S*)-3-methyl-2-[(3-(trifluoromethyl)benzyl)amino]butanoyl}-2-oxo-1-(3-phenylpropyl)-4-imidazolidinecarboxamide;

(4*S*)-*N*-{[(1*R*)-1-[(3*αS*,4*S*,6*S*,7*αR*)-hexahydro-3*α*,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl}-3-{(2*S*)-2-[(1,1'-biphenyl)-4-ylmethyl]amino]-3-methylbutanoyl}-2-oxo-1-(3-phenylpropyl)-4-imidazolidinecarboxamide;

9*H*-fluoren-9-ylmethyl (1*S*)-1-((5*S*)-5-[(1*R*)-1-[(3*αS*,4*S*,6*S*,7*αR*)-hexahydro-3*α*,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]amino)carbonyl]-2-oxo-3-[(2-phenyl-4-quinolinyl)methyl]imidazolidinyl]carbonyl}-2-methylpropylcarbamate;

*N-((1*S*)-1-{{(5*S*)-5-{{(1*R*)-1-[(3*α*S, 4*S*, 6*S*, 7*α*R)-hexahydro-3*α*, 5, 5-trimethyl-4, 6-methano-1, 3, 2-benzodioxaborol-2-yl]propyl}-amino)carbonyl]-2-oxo-3-(3-phenylpropyl)imidazolidinyl]carbonyl}-2-methylpropyl)-2-chloronicotinamide;*

*(4*S*)-N-{{(1*R*)-1-[(3*α*S, 4*S*, 6*S*, 7*α*R)-hexahydro-3*α*, 5, 5-trimethyl-4, 6-methano-1, 3, 2-benzodioxaborol-2-yl]propyl}-3-{(2*S*)-2-[(4-butylbenzoyl)amino]-3-methylbutanoyl}-2-oxo-1-(3-phenylpropyl)-4-imidazolidinecarboxamide;*

*isobutyl (1*S*)-1-{{(5*S*)-5-{{(1*R*)-1-[(3*α*S, 4*S*, 6*S*, 7*α*R)-hexahydro-3*α*, 5, 5-trimethyl-4, 6-methano-1, 3, 2-benzodioxaborol-2-yl]propyl}amino)carbonyl]-2-oxo-3-(3-phenylpropyl)imidazolidinyl]carbonyl}-2-methylpropylcarbamate;*

*(4*S*)-N-{{(1*R*)-1-[(3*α*S, 4*S*, 6*S*, 7*α*R)-hexahydro-3*α*, 5, 5-trimethyl-4, 6-methano-1, 3, 2-benzodioxaborol-2-yl]propyl}-3-{(2*S*)-2-[(benzoylamino)carbonyl]amino}-3-methylbutanoyl}-2-oxo-1-(3-phenylpropyl)-4-imidazolidinecarboxamide;*

*(4*S*)-N-{{(1*R*)-1-[(3*α*S, 4*S*, 6*S*, 7*α*R)-hexahydro-3*α*, 5, 5-trimethyl-4, 6-methano-1, 3, 2-benzodioxaborol-2-yl]propyl}-3-{(2*S*)-3-methyl-2-(1-naphthoylamino)butanoyl}-2-oxo-1-(3-phenylpropyl)-4-imidazolidinecarboxamide;*

*(4*S*)-N-{{(1*R*)-1-[(3*α*S, 4*S*, 6*S*, 7*α*R)-hexahydro-3*α*, 5, 5-trimethyl-4, 6-methano-1, 3, 2-benzodioxaborol-2-yl]propyl}-3-{(2*S*)-2-(acetylamino)-3-methylbutanoyl}-2-oxo-1-(3-phenylpropyl)-4-imidazolidinecarboxamide;*

(4*S*)-*N*-{[(1*R*)-1-[(3*αS*,4*S*,6*S*,7*αR*)-hexahydro-3*α*,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl}-3-[(2*S*)-2-(benzoylamino)-3-methylbutanoyl]-2-oxo-1-(3-phenylpropyl)-4-imidazolidinecarboxamide;

benzyl (5*S*)-5-[(1*R*)-1-[(3*αS*,4*S*,6*S*,7*αR*)-hexahydro-3*α*,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-butenyl]amino)carbonyl]-2-oxo-3-[(2*E*)-3-phenyl-2-propenyl]-1-imidazolidinecarboxylate; and

benzyl (5*S*)-5-[(1*R*)-1-[(3*αS*,4*S*,6*S*,7*αR*)-hexahydro-3*α*,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-butenyl]amino)carbonyl]-3-(2-anilino-2-oxoethyl)-2-oxo-1-imidazolidinecarboxylate.

7. (currently amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 1, or a pharmaceutically acceptable salt form ~~or prodrug~~ thereof.

8. (canceled)

9. (canceled)

10. (canceled)

11. (canceled)

12. (canceled)

13. (canceled)

14. (previously canceled)

15. (previously canceled)

16. (previously canceled)

17. (previously canceled)

18. (previously canceled)

19. (previously canceled)

20. (previously canceled)

21. (previously canceled)